A Breakthrough in HPV Detection
Molbio Diagnostics Limited, a leader in point-of-care molecular diagnostics, has launched its latest innovation—Truenat HPV-HR Plus. This chip-based RT-PCR test enables the rapid and decentralized detection of eight high-risk human papillomavirus (HPV) genotypes, which together account for over 96% of cervical cancer cases worldwide.
Strong Validation Backed by National Programs
The multicentric validation of Truenat HPV-HR Plus received support from the Grand Challenges India initiative, Biotechnology Industry Research Assistance Council (BIRAC), and the Department of Biotechnology (DBT), Government of India. These efforts were part of the program titled “Validating Indigenous Human Papilloma Virus (HPV) Tests for Cervical Cancer Screening in India”, making Truenat one of the most trusted, homegrown diagnostic tools for cervical cancer screening in the country.
Addressing India’s Cervical Cancer Burden
India continues to carry a disproportionate share of the global cervical cancer burden, accounting for nearly 25% of global cases. Each year, more than 1,23,000 Indian women are newly diagnosed, and around 77,000 lose their lives to this preventable disease. Despite available preventive measures, cervical cancer remains the second most common cancer among Indian women.
Government Endorsement of Homegrown Innovation
Recognizing the need for indigenous solutions, Rajesh S. Gokhale, Secretary of the Department of Biotechnology, Ministry of Science & Technology, Government of India, praised the new test. He stated, “Truenat HPV-HR Plus represents the kind of diagnostic innovation we need — dependable, scientifically rigorous, locally developed, and built to serve our public health system. It’s a huge step forward in strengthening cervical cancer screening across India.”
Fast, Simple, and Reliable Testing
As reported by biospectrumindia, Truenat HPV-HR Plus offers a simple, fast, and reliable method for detecting high-risk HPV infections. The portable device uses cervical swab samples collected by a clinician and delivers highly accurate results within just 60 minutes.
Moreover, the test is easy to operate, maintains high stability at room temperature, and requires minimal biosafety measures. Its design ensures that it can be used effectively both in laboratory settings and near-patient environments, making it a versatile tool in the fight against cervical cancer.